cancer screening project banner
survey reveals Cervical Cancer Screening rates in Delaware

report The Delaware Behavioral Risk Factor Survey (BRFS), which was conducted by the Behavioral Risk Factor Surveillance System (BRFSS) in a cooperative effort by the Delaware Division of Public Health and the U.S. Centers for Disease Control and Prevention (CDC), collected data on cervical cancer screening in Delaware annually from 1995 to 2000 and biannually since then. In 2016, the BRFS showed that:
  • 79% percent of Delaware women 21-65 years of age reported that they had had a Pap test within the previous three years. By comparison, the nation median was 80% of women 21-65 years of age who reported having had a Pap test within the previous three years.
  • In 2016, Delaware ranked 33rd (79%) for women 21-65 years of age receiving a Pap test in the past three years.
In Delaware, women 21-65 years of age with an annual household income of $25,000-34,999 had the lowest prevalence of receiving a Pap test within the past three years.
make sure you are up-to-date on the new Cervical Cancer Screening Recommendations

free update image The United States Preventive Services Task Force (USPSTF) recommends screening for cervical cancer every three years with cervical cytology alone in women aged 21 to 29 years. For women aged 30 to 65 years, the USPSTF recommends screening every three years with cervical cytology alone, every five years with high-risk human papillomavirus (hrHPV) testing alone, or every five years with hrHPV testing in combination with cytology (co-testing).
This recommendation replaces the 2012 USPSTF recommendation. The major change in the current recommendation is that the USPSTF now recommends screening every five years with hrHPV testing alone as an alternative to screening every three years with cervical cytology alone among women aged 30 to 65 years.  Read the final recommendation statement.
encourage your patients to take advantage of no-cost screening & treatment programs

If your patient doesn't have insurance or they can't afford a Pap test, the Screening for Life program could cover the cost of the screening for them. Learn more about the program here.
If your patient should be diagnosed with cervical cancer and they can't afford treatment, the Delaware Cancer Treatment Program provides free cancer treatment for up to two years. Cancer Care Coordinators help guide your patient through treatment, scheduling visits with doctors and making sure they get the care they need.
healthy delaware now offers free patient education resources to promote cervical cancer screening in your waiting room  

A systematic review by The Community Guide has shown that the use of small media is effective in increasing cervical cancer screening by Pap test. Small media include videos and printed materials such as letters, brochures, and newsletters. These materials can be used to inform and motivate people to be screened for cancer. They can provide information tailored to specific individuals or targeted to general audiences.
The Healthy Delaware website is a great resource for providers and their staff to order copies of educational materials for your practice. Click here to view the materials available to you at NO COST. There is even a short two-minute video available for you to play in the waiting room that discusses the importance of cervical cancer screening and what the patient can expect from the test.

video reviews current guidelines for cervical cancer screening for various populations

video VIDEO: Cervical Cancer Screening: Applying Guidelines to Case-Based Scenarios
This 1.5-hour video created by the Association of Reproductive Health Professionals was developed to educate health care providers about the current guidelines for cervical cancer screening for various populations.
Learning Objectives:
  • Explain the current guidelines for cervical cancer screening for various populations
  • Identify vulnerable/underserved populations and describe relevant barriers to cervical cancer screening and treatment
  • Counsel patients on updated cervical cancer screening guidelines specific to their age, screening history, and health status
  • Apply cervical cancer screening counseling strategies for various populations
HPV Vaccination is Cancer Prevention

Thinkstock vaccine vials Carcinogenic types of human papillomavirus (HPV) are the primary, etiologic, infectious agents that cause virtually all cases of cervical cancer. HPV type 16 (HPV-16) and HPV type 18 (HPV-18) are most often associated with invasive disease.
Based on solid evidence, vaccination against HPV-16/HPV-18 is effective in preventing HPV infection in HPV-naive individuals and is associated with a reduced incidence of cervical intraepithelial neoplasia 2 and 3. By extrapolation, these vaccines should also be associated with a reduced incidence of cervical cancer.
According the Centers for Disease Control and Prevention (CDC), the HPV vaccine  protects against the types of HPV that most often cause not only cervical cancer but also vaginal, vulvar, anal, and oral cancers. It is recommended for preteens (both boys and girls) aged 11 to 12 years, but can be given as early as age 9 and until age 26.
delaware dhss report details cervical cancer incidence and mortality rates in delaware

report icon In a report issued by the Delaware Department of Health and Social Services (DE DHSS), Cancer Incidence and Mortality in Delaware 2010-2014, it stated that Delaware ranked 12th in the U.S. 
for cervical cancer incidence (13 th in 2009-2013) . The report also included the following statistics:
  • In 2010-2014, there were 211 cervical cancer cases (1% of all female cancer cases) diagnosed in Delaware.
  • Non-Hispanic Caucasians accounted for 70% of cervical cancer cases.
  • Non-Hispanic Caucasians in Delaware (8.6 per 100,000) had a statistically significantly higher cervical cancer incidence rate compared to non-Hispanic Caucasians in the U.S. (6.9 per 100,000).
For 2010-2014, Delaware ranked 6 th in the U.S. for cervical cancer mortality (15 th in 2009-2013) 11.
  • In 2010-2014, there were 78 female deaths (2% of all female cancer deaths) from cervical cancer in Delaware.
  • Non-Hispanic Caucasian females accounted for 68% of cervical cancer deaths.
  • From 2000-2004 to 2010-2014, mortality rates for cervical cancer increased 3% in Delaware and decreased 12% in the U.S. 
join quality insights in our efforts to Improve HPV Vaccination Rates in Delaware

improvement icon Quality Insights is spearheading an exciting new program for medical providers to increase Human Papilloma Virus (HPV) vaccination rates in Delaware. As part of this program, we will engage providers and staff in interactive, collaborative discussions on the HPV vaccine, including cancer prevention, immunogenicity, safety, guidelines, addressing parental concerns and workflow assistance. Please consider joining us in this important initiative at NO COST to your practice.
Benefits of Participation:
  • Tailored presentation of the Centers for Disease Control and Prevention's (CDC) "You are the Key to HPV Cancer Prevention"
  • Workflow assessment
  • Monthly HPV e-newsletters including recorded webinars, CDC resources, and other tips for your practices
  • Free CDC HPV patient/parent resources and provider resources
  • Review of Delaware Immunization Registry (DelVax) reports and discussion for implementation of evidenced-based workflows to improve HPV vaccination rates
If you are interested in participating in this program and would like more information, please email Lisa Gruss or call 1.302.299.7284.
contact information

For more details about the Cancer Screening Quality Improvement Projects being led by Quality Insights , please contact Sarah Toborowski or Lisa Gruss.

Quality Insights logo      
This publication was supported by the Cooperative Agreement Number NU58DP006349-02 from the Centers for Disease Control and Prevention. 
Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease 
Control and Prevention. Publication number DEDPH-CS -020419